Search Clinical Trials in the EU

Duration

Visits

Phase

Intake methods

Post-Trial Drug Access

Drugs

Locations

Clinical Specialty

401-420 of 847 trials

Ibrutinib for Autoimmune Hemolytic Anemia in CLL Patients

We are studying whether ibrutinib can effectively treat autoimmune hemolytic anemia in patients with chronic lymphocytic leukemia or similar conditions. The trial will also look at the safety and quality of life during treatment.

Chronic Lymphocytic Leukemia (CLL)>2 yearsEfficacy phase (II)≤5 visits Post-Trial Drug Access No Placebo Standard MedicinesHematologyOncology

Early Alzheimer's Disease: Sabirnetug Infusions

We are studying whether intravenous sabirnetug can slow cognitive decline in people with early Alzheimer's disease compared to a placebo. This trial aims to find new ways to help manage symptoms and improve quality of life.

Early Alzheimer's Disease1-2 yearsEfficacy phase (II)16-20 visits Post-Trial Drug Access Investigational Medicines Cost ReimbursementNeurology

Testosterone Supplementation for Obese Men with Type 2 Diabetes

We are studying whether intramuscular testosterone can reduce liver fat in obese men with low testosterone and type 2 diabetes. This trial will also look at the long-term effects on metabolic health.

HypogonadismType 2 Diabetes Mellitus (T2DM)Prediabetes>2 yearsMonitoring phase (IV)Post-Trial Drug Access Investigational MedicinesDiabetologyEndocrinologyInternal Medicine

Advanced Solid Tumors: BI-1206 with Pembrolizumab

We are studying a new treatment combining BI-1206 and pembrolizumab for patients with advanced solid tumors. This trial aims to find a safe dose and understand how well this combination works for those with specific types of cancer.

Malignant Solid Tumor>2 yearsSafety phase (I)Efficacy phase (II)>20 visits Post-Trial Drug Access No Placebo Investigational Medicines Cost ReimbursementInternal MedicineOncology

Multiple Myeloma: Mezigdomide vs. Pomalidomide

We are studying whether a new drug, mezigdomide, combined with bortezomib and dexamethasone, is more effective than pomalidomide with the same drugs for patients with relapsed or refractory multiple myeloma.

Relapsed or Refractory Multiple Myeloma≤3 monthsConfirmation phase (III)>20 visits Post-Trial Drug Access No Placebo Investigational Medicines Cost ReimbursementHematologyOncology

Non-Small Cell Lung Cancer: Osimertinib with Datopotamab Deruxtecan

We are studying the safety and effectiveness of combining osimertinib with datopotamab deruxtecan in patients with advanced non-small cell lung cancer that has an EGFR mutation. This trial aims to see if the combination works better than osimertinib alone.

Non-Squamous Non-Small Cell Lung Cancer>2 yearsConfirmation phase (III)Post-Trial Drug Access No Placebo Standard Medicines Partially RemoteOncology

Difelikefalin for Itching in Adolescents on Hemodialysis

We are studying whether difelikefalin is safe for adolescents aged 12 to 17 who have moderate-to-severe itching related to long-term kidney disease. This trial aims to help improve care for young patients undergoing hemodialysis.

Generalized ItchingChronic Kidney Diseases3-6 monthsEfficacy phase (II)>20 visits Post-Trial Drug Access No Placebo Standard Medicines Partially RemoteDermatologyNephrologyPediatrics

Pegozafermin for Metabolic Dysfunction-Associated Steatohepatitis (MASH)

We are studying whether pegozafermin can improve liver health in people with MASH and fibrosis compared to a placebo. This trial will help us understand its safety and effectiveness over time.

Nonalcoholic Fatty Liver Disease>2 yearsConfirmation phase (III)11-15 visits Post-Trial Drug Access Investigational Medicines Cost Reimbursement Partially RemoteEndocrinologyHepatology

Melanoma Treatment: Short vs. Long Immunotherapy

We are studying whether 6 months of immunotherapy after surgery is as effective as 12 months for patients with high-risk malignant melanoma. This could help determine the best treatment duration for better outcomes.

Skin Cancer (Melanoma)Confirmation phase (III)Post-Trial Drug Access No Placebo Standard MedicinesDermatologyOncology

Inebilizumab for Children with Neuromyelitis Optica Spectrum Disorder

We are studying how the medication inebilizumab affects children and adolescents with NMOSD. The trial will help us learn about its safety and how it impacts their health and daily life.

Neuromyelitis Optica Spectrum Disorder1-2 yearsEfficacy phase (II)≤5 visits Post-Trial Drug Access No Placebo Standard MedicinesNeurology

Mucopolysaccharidosis IIIA: Gene Therapy Study

We are testing a new gene therapy called UX111 for individuals with Mucopolysaccharidosis IIIA. The goal is to see if it is safe and effective in treating this condition.

Mucopolysaccharidosis III>2 yearsSafety phase (I)Efficacy phase (II)11-15 visits Post-Trial Drug Access No Placebo Investigational Medicines Cost Reimbursement Partially RemoteHematologyInternal MedicineNeurologyPediatrics

Non-Functioning Pituitary Adenomas: Cabergoline Treatment

We are studying the effects of cabergoline on non-functioning pituitary adenomas. This trial aims to see if this medication can improve treatment outcomes for patients.

Non-functioning Pituitary Adenoma>2 yearsMonitoring phase (IV)Post-Trial Drug Access No Placebo Standard Medicines Partially RemoteEndocrinologyOncology

Venous Malformations: Enalapril Study

We are testing the medication enalapril in adults with painful venous malformations to see if it helps reduce pain and improve quality of life. We will also look at any changes in the size of the malformations.

Venous Malformation>2 yearsEfficacy phase (II)6-10 visits Post-Trial Drug Access No Placebo Standard Medicines Partially RemoteInternal MedicineOrthopedics and Traumatology

Cerebral Amyloid Angiopathy: ALN-APP Treatment Study

We are studying a new treatment called ALN-APP for patients with Cerebral Amyloid Angiopathy. The goal is to see if it helps reduce new brain bleeding and improve overall brain health.

Cerebral Amyloid Angiopathy1-2 yearsEfficacy phase (II)11-15 visits Post-Trial Drug Access Investigational Medicines Partially RemoteNeurology

Chronic Lymphocytic Leukemia: Acalabrutinib Treatment Study

We are investigating whether acalabrutinib is safe and effective for adults with chronic lymphocytic leukemia and heart problems. This study compares it to other treatment options available for these patients.

Chronic Lymphocytic Leukaemia with Cardiac Impairment>2 yearsMonitoring phase (IV)16-20 visits Post-Trial Drug Access No Placebo Standard Medicines Partially RemoteCardiologyHematology

Myelodysplastic Syndromes: Ivosidenib vs. Azacitidine

We are studying the effects of a new drug, ivosidenib, in adults with myelodysplastic syndromes who have an IDH1 mutation. The goal is to understand its effectiveness and safety compared to azacitidine.

Myelodysplastic Syndrome (MDS)Hypomethylating Agent Naive Myelodysplastic Syndromes>2 yearsConfirmation phase (III)Post-Trial Drug Access No Placebo Investigational Medicines Partially RemoteHematologyOncology

Advanced Lung Cancer: STX-241 Study

We are testing a new oral anticancer drug, STX-241, for patients with advanced non-small cell lung cancer resistant to standard treatments. The goal is to evaluate its safety and potential effectiveness.

Metastatic Non-Small Cell Lung CancerSafety phase (I)Efficacy phase (II)≤5 visits Post-Trial Drug Access No Placebo Investigational Medicines Cost ReimbursementOncologyPulmonology

Rheumatoid Arthritis: FBL-MTX Injection Study

We are investigating a new injectable treatment for moderate-to-severe rheumatoid arthritis in patients who haven't used DMARDs or have had issues with oral methotrexate. The study will evaluate how well it works and its safety.

Rheumatoid Arthritis3-6 monthsEfficacy phase (II)6-10 visits Post-Trial Drug Access No Placebo Standard MedicinesInternal MedicineRheumatology

Niemann-Pick Disease Type C: N-Acetyl-L-Leucine Study

We are investigating whether N-Acetyl-L-Leucine can improve symptoms and quality of life for individuals with Niemann-Pick disease type C. The study also looks at the safety of this treatment for both older and younger patients.

Niemann-Pick Disease Type C3-6 monthsConfirmation phase (III)≤5 visits Post-Trial Drug Access Investigational Medicines Partially RemoteHematologyNeurology

Prurigo Nodularis: Barzolvolimab Study

We are testing a new medication, barzolvolimab, for people with prurigo nodularis to see if it helps reduce itching and improve skin lesions. The study will also look at the safety of this treatment and its effects on quality of life.

Prurigo Nodularis6-12 monthsEfficacy phase (II)6-10 visits Post-Trial Drug Access Investigational MedicinesAllergologyDermatology

Search Clinical Trials in the European Union